FEMY · Insider Trading
Femasys Inc. Common Stock
Every open-market purchase and sale reported by FEMY officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-11 | Kathy Lee-Sepsick | Chief Executive Officer | Buy | +15,625 | +$50.00K |
| 2026-08-11 | Charles Larsen | Director | A | +880 deriv. | — |
| 2026-08-11 | John Charles Canning | Chief Operating Officer | Buy | +4,375 | +$14.00K |
| 2026-08-11 | Kenneth D. Eichenbaum | Director | A | +880 deriv. | — |
| 2026-08-11 | Jeffrey Gerald Mifek | Chief Clinical-Medical Affairs | Buy | +3,125 | +$10.00K |
| 2026-08-11 | Jeffrey Gerald Mifek | Chief Clinical-Medical Affairs | A | +6,250 deriv. | — |
| 2026-08-11 | Jeremy Alexander Sipos | Chief Technology Officer | Buy | +3,125 | +$10.00K |
| 2026-08-11 | Alistair Milnes | Director | A | +880 deriv. | — |
| 2026-08-11 | Edward R Uzialko | Director | A | +880 deriv. | — |
| 2026-08-11 | Dov Elefant | Chief Financial Officer | Buy | +15,625 | +$50.00K |
| 2026-04-01 | John Charles Canning | Chief Operating Officer | A | +150,000 deriv. | — |
| 2026-03-27 | Charles Larsen | Director | A | +34,122 deriv. | — |
| 2026-03-27 | Dov Elefant | Chief Financial Officer | A | +34,122 deriv. | — |
| 2026-03-27 | Kenneth D. Eichenbaum | Director | A | +102,366 deriv. | — |
| 2026-03-27 | Kathy Lee-Sepsick | Chief Executive Officer | A | +68,244 deriv. | — |
| 2026-03-20 | Kenneth D. Eichenbaum | Director | A | +35,200 deriv. | — |
| 2026-02-20 | Dov Elefant | Chief Financial Officer | A | +342,000 deriv. | — |
| 2026-02-20 | Kathy Lee-Sepsick | Chief Executive Officer | A | +729,000 deriv. | — |
| 2026-02-17 | Jeremy Alexander Sipos | Chief Technology Officer | A | +80,000 deriv. | — |
| 2025-11-19 | Kathy Lee-Sepsick | Chief Executive Officer | I | +204,732 deriv. | — |
| 2025-11-12 | Charles Larsen | Director | I | +102,366 deriv. | — |
| 2025-11-12 | Dov Elefant | Chief Financial Officer | I | +102,366 deriv. | — |
| 2025-08-28 | Kathy Lee-Sepsick | Chief Executive Officer | I | +48,535 | — |
| 2025-08-28 | Dov Elefant | Chief Financial Officer | I | +38,828 | — |
| 2025-07-01 | Kelley Stinson Nicholas | Chief Commercial Officer | A | +100,000 deriv. | — |
| 2025-06-27 | Edward R Uzialko | Director | A | +17,600 deriv. | — |
| 2025-06-27 | Joshua Silverman | Director | A | +17,600 deriv. | — |
| 2025-06-27 | Alistair Milnes | Director | A | +17,600 deriv. | — |
| 2025-06-27 | Charles Larsen | Director | A | +17,600 deriv. | — |
| 2025-06-04 | Dov Elefant | Chief Financial Officer | I | +19,608 | +$20.00K |
| 2025-06-04 | Kathy Lee-Sepsick | Chief Executive Officer | I | +34,314 | +$35.00K |
| 2025-06-04 | Charles Larsen | Director | I | +24,510 | +$25.00K |
| 2025-06-04 | Daniel Scott Currie | Chief Operating Officer | I | +19,608 | +$20.00K |
| 2025-01-30 | Christine E Thomas | Chief Reg & Clinical Officer | A | +107,372 deriv. | — |
| 2025-01-30 | Kathy Lee-Sepsick | Chief Executive Officer | A | +442,902 deriv. | — |
| 2025-01-30 | Daniel Scott Currie | Chief Operating Officer | A | +229,197 deriv. | — |
| 2025-01-30 | Dov Elefant | Chief Financial Officer | A | +186,345 deriv. | — |
| 2024-07-15 | Alistair Milnes | Director | A | +17,600 deriv. | — |
| 2024-07-15 | Edward R Uzialko | Director | A | +17,600 deriv. | — |
| 2024-07-15 | Charles Larsen | Director | A | +17,600 deriv. | — |
| 2024-07-15 | Joshua Silverman | Director | A | +17,600 deriv. | — |
| 2024-02-13 | Richard D. Spector | Chief Commercial Officer | A | +100,000 deriv. | — |
| 2024-02-02 | Daniel Scott Currie | Chief Operating Officer | A | +61,900 deriv. | — |
| 2024-02-02 | Kathy Lee-Sepsick | Chief Executive Officer | A | +204,900 deriv. | — |
| 2024-02-02 | Dov Elefant | Chief Financial Officer | A | +84,000 deriv. | — |
| 2024-02-02 | Christine E Thomas | SVP, Regulatory & Clinical | A | +32,600 deriv. | — |
| 2023-11-22 | Joshua Silverman | Director | A | +17,000 deriv. | — |
| 2023-11-01 | Christine E Thomas | SVP, Regulatory & Clinical | A | +60,000 deriv. | — |
| 2023-07-03 | Kathy Lee-Sepsick | Chief Executive Officer | A | +542,300 deriv. | — |
| 2023-07-03 | Dov Elefant | Chief Financial Officer | A | +309,900 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Kathy Lee-Sepsick | Chief Executive Officer | 19,236 | $27.32K |
| Dov Elefant | Chief Financial Officer | 15,625 | $22.19K |
| Edward R Uzialko | Director | 7,898 | $11.22K |
| Daniel Scott Currie | Chief Operating Officer | 5,425 | $7.70K |
| John Charles Canning | Chief Operating Officer | 4,375 | $6.21K |
| Jeremy Alexander Sipos | Chief Technology Officer | 3,125 | $4.44K |
| Jeffrey Gerald Mifek | Chief Clinical-Medical Affairs | 3,125 | $4.44K |
| Charles Larsen | Director | 3 | $4 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the FEMY quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.